Mexico

COFEPRIS, operating under the Secretaria de Salud (SSA), serves as Mexico's primary regulatory authority for health products including pharmaceuticals, medical devices, diagnostics, and digital health solutions. The principal governing legislation is the Ley General de Salud and its associated Reglamento de Insumos para la Salud, which establish the legal framework for the registration, import, distribution, and commercialization of health products in Mexico. All health products must obtain a Registro Sanitario (sanitary registration) prior to commercialization, and COFEPRIS evaluates applications through its Commission for New Molecules and its Directorate of Medical Devices, depending on product category. The agency also conducts post-market surveillance and has the authority to suspend or cancel registrations for non-compliance.

A local legal representative or Mexican legal entity is required to hold the Registro Sanitario, making a local regulatory affairs partner or distributor arrangement essential for foreign manufacturers. COFEPRIS accepts dossiers structured according to the Common Technical Document (CTD) format for pharmaceuticals and increasingly aligns with international standards for medical devices, including references to IMDRF guidelines. Mexico is a member of the Pan American Network for Drug Regulatory Harmonization (PANDRH) and has pursued regulatory convergence with other Latin American markets. A significant recent reform was the 2020 dissolution and subsequent reconstitution of COFEPRIS's internal structure under the broader healthcare system overhaul initiated by the Lopez Obrador administration, which also introduced INSABI (later replaced by IMSS-Bienestar in 2023), creating transitional uncertainty in procurement linkages. Applicants should also note that COFEPRIS has introduced expedited pathways for products previously approved by recognized stringent regulatory authorities (SRAs) such as the FDA, EMA, Health Canada, and others.

Public procurement in Mexico is governed by the Ley de Adquisiciones, Arrendamientos y Servicios del Sector Publico and administered through multiple channels. The primary public payers and procuring entities include the Instituto Mexicano del Seguro Social (IMSS), the Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), the Secretaria de Salud (SSA), and the recently expanded IMSS-Bienestar program, which absorbed the functions of INSABI in 2023 to serve the uninsured population. Federal consolidated tenders, historically managed through IMSS on behalf of multiple public institutions, represent the largest procurement channel and are published via the CompraNet platform. State-level health secretariats (Servicios Estatales de Salud, SESA) also conduct their own procurement for products not covered by federal consolidation, creating a decentralized secondary procurement tier. Inclusion on the Catalogo de Insumos del Sector Salud (CISS) or relevant institutional formularies is a prerequisite for participation in most public tenders, and pricing negotiations are conducted through the Comision Interinstitucional del Cuadro Basico y Catalogo de Insumos del Sector Salud (CICBCIS).

The private sector in Mexico represents a significant and growing channel, served through retail pharmacy chains, private hospital networks, and distributor agreements; it operates largely independently of public procurement processes and does not require separate pricing approvals, though Registro Sanitario is still mandatory. Mexico has historically engaged with international procurement organizations including PAHO's Revolving Fund for vaccine procurement and, to a lesser extent, UNICEF and the Global Fund for specific disease-area programs. The 2020-2022 transition saw Mexico experiment with direct procurement through UNOPS as an alternative to traditional domestic tender mechanisms, a controversial policy that has since been wound down in favor of returning to institutional procurement norms under IMSS-Bienestar. There is no formal domestic manufacturing preference policy equivalent to some other markets, but the government has expressed strategic interest in strengthening national pharmaceutical and device manufacturing capacity, and locally manufactured or packaged products may carry practical advantages in certain tender evaluations.